Beijing Genecradle Therapeutics Co.,Ltd. is a pioneering Chinese national high-tech enterprise at the forefront of gene therapy drugs development mediated by cutting-edge AAV vector delivery technology. Our mission is to bridge the gap between basic research and clinical pratice, transforming China's rare disease gene therapy from the laboratory bench to patients' bed-side, and ultimately, to the global marketplace, bringing hope and relief to countless patients and their families. 
With a focus on hereditary neuromuscular diseases, genetic metabolic diseases, lysosomal storage disorders, and ophthalmic diseases, we relentlessly pursue the development of innovative gene therapy solutions. By fostering research and development, optimizing production processes, and facilitating clinical application of these rare disease treatment, we gain a profounder comprehension of life, health, and the potential of gene therapy. 
Moreover, we have transcended the boundaries of rare diseases, applying our expertise in gene therapy technology and products to the treatment and rehabilitation of chronic illness and other significant heath challenges. This groundbreaking approach accelerates the accessibility of gene therapy, ensuring they become a reality for patients worldwide.